AltPep Analysis: $76M Raised
What is AltPep?
AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting toxic soluble oligomers. The company's platform uses custom-designed peptides to bind selectively to alpha-sheet structures, a molecular trigger identified through decades of research by the Daggett Research Group. Their lead program focuses on Alzheimer’s disease with a preclinical compound, SOBIN-AD, showing increased clearance of Aβ toxic oligomers and inhibition of plaque formation.
Location
Seattle, United States
Employees
11-50
Founded
2019
Funding Status
Series B
Product Features & Capabilities
- Custom-designed peptides for therapeutics
- SOBIN-AD for Alzheimer’s treatment
- SOBA Diagnostics for early blood-based detection of amyloid diseases
Use Cases
Detect amyloid diseases via blood tests before symptoms appear; Neutralize toxic soluble oligomers in Alzheimer’s patients; Monitor disease progression using blood-based diagnostics; Develop treatments for Parkinson’s and other amyloid diseases
Other Considerations
Presented new preclinical data at AAIC 2025; Lead compound SOBIN-AD shows increased clearance of Aβ toxic oligomers; Founded by Valerie Daggett, PhD, Endowed Professor of Bioengineering at UW; Decades of research culminated in alpha-sheet discovery
See something that needs updating? Suggest edits to this profile.